Benzadiazaborocarboxamides, their preparation, pharmaceutical compositions and applications

By designing benzodiazepine carboxamide compounds, the side effects of existing PHD inhibitors have been addressed, achieving highly efficient inhibition of PHD2 and regulation of the HIF signaling pathway, providing a new treatment option for diseases such as renal anemia.

CN123106728APending Publication Date: 2026-11-17CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611436919.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing PHD inhibitors have side effects in clinical applications, such as roxadustat causing thrombosis and epilepsy. There is a need to develop novel PHD inhibitors that combine activity and safety to treat renal anemia.

Method used

We have provided a class of benzodiazepine carboxamide compounds and their pharmaceutically acceptable salts, which, through specific structural design, exhibit significant PHD2 inhibitory activity and can effectively regulate the HIF signaling pathway for the treatment of ischemic diseases such as renal anemia.

Benefits of technology

The compounds exhibit nanomolar inhibitory activity against PHD2, with some compounds showing activity superior to or equivalent to the positive control roxadustat. They can effectively regulate the HIF signaling pathway and are used to treat diseases such as renal anemia and chronic kidney disease anemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106728A_ABST
    Figure CN123106728A_ABST
Patent Text Reader

Abstract

This invention discloses a benzodiazepine formamide compound, its preparation method, pharmaceutical composition, and applications, wherein the compound is shown in formula (I). This invention also discloses that the above compound exhibits significant inhibitory activity against prolyl hydroxylase 2 (PHD2) and demonstrates good HIF / HRE transcriptional activation. Fluorescence polarization assays show that the above compound can competitively bind to the PHD2 (181-426) protein, with inhibitory activity reaching the nanomolar level, and some compounds showing IC50... 50 The values ​​are comparable to or better than those of the positive control roxadustat. The compounds of this invention can be used to treat PHD2 / HIF pathway-related diseases, especially renal anemia and chronic kidney disease anemia. This invention provides an option for the treatment of anemia and related ischemic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a class of benzodiazepine carboxamide compounds, their preparation methods, pharmaceutical compositions, and applications, and particularly to a class of benzodiazepine carboxamide compounds that can be prepared as drugs for treating ischemic diseases, their preparation methods, pharmaceutical compositions, and applications. Background Technology

[0002] Chronic kidney disease (CKD) is a major global public health problem, and it is projected to become the fifth leading cause of death worldwide by 2040. Renal anemia is a common complication of CKD¹, and its incidence gradually increases with the prevalence of CKD. Studies show that in China, the prevalence of anemia in non-dialysis CKD patients is approximately 50%, while the incidence can reach as high as 91.6%–98.2% after entering the dialysis stage. Currently, the main treatments for renal anemia include erythropoiesis stimulants, iron supplements, and hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors. Among these, PHD inhibitors, as oral small-molecule inhibitors, are convenient to administer and have good therapeutic effects, and have become a major research focus in recent years.

[0003] PHDs are iron- and 2-oxoglutarate (2OG)-dependent dioxygenases, mainly including three isoforms: PHD1, PHD2, and PHD3. Under conditions where oxygen, iron, and 2OG are present, PHDs can hydroxylate proline residues in the α subunit of hypoxia-inducible factor (HIF), thereby regulating the HIF pathway. Under normoxic conditions, PHDs catalyze the hydroxylation of proline residues in HIF-α (HIF-1α: Pro402 and Pro564; HIF-2α: Pro405 and Pro531). The hydroxylated HIF-α rapidly binds to the tumor suppressor protein VHL, ultimately forming an E3 ubiquitin-protein ligase complex, which is then rapidly degraded by the proteasome. Conversely, under hypoxic conditions, PHD hydroxylation function is restricted, and unhydroxylated HIF-α translocates into the nucleus, where it binds to HIF-β to form HIF heterodimers. This activates the HIF signaling pathway, thereby initiating the expression of downstream genes (such as erythropoietin, EPO), stimulating erythropoiesis in the bone marrow, and thus improving renal anemia.

[0004] Currently, six PHD inhibitors have been successfully marketed for the treatment of renal anemia: roxadustat, daprodustat, vadadustat, enarodustat, molidustat, and desidustat. However, these drugs still have certain risks in clinical application. For example, the first marketed drug, roxadustat, has serious side effects such as thrombosis and seizures. Therefore, there is still a need to develop a novel PHD inhibitor that combines activity and safety, and this invention provides a new direction for research. Summary of the Invention

[0005] Purpose of the invention: In view of the problems existing in the clinical application of PHD inhibitors, the present invention aims to provide a class of benzodiazepine boron carboxamide compounds with potential for the treatment of renal anemia, preparation methods, pharmaceutical compositions and applications.

[0006] Technical solution: As a first aspect of the present invention, the present invention provides benzodiazepine formamide compounds or pharmaceutically acceptable salts thereof, said compounds being as shown in formula (I):

[0007]

[0008] in:

[0009] R 1 Represents hydrogen, hydroxyl group, substituted or unsubstituted C6-C 10 Arylsulfonyloxy, substituted C6-C 10 The number of substituents in the arylsulfonyloxy group is one or two, and the substituents are C1-C4 alkyl, C1-C4 alkoxy, cyano, halogen or C1-C4 haloalkoxy;

[0010] n represents 0 or 1;

[0011] R 2 Represents C1-C2 carboxylalkyl, carboxyl, 5-6 nitrogen-containing heteroaryl, and p-cyanophenyl;

[0012] R 3 It represents hydrogen or C1-C4 alkyl.

[0013] Preferably, R 1 Represents hydrogen, hydroxyl, substituted or unsubstituted benzenesulfonyloxy, wherein the number of substituents in substituted benzenesulfonyloxy is 1 or 2, and the substituents are methyl, methoxy, cyano, chlorine or trifluoromethoxy;

[0014] n represents 0;

[0015] R 2 Represents carboxymethyl, pyridazinyl, and p-cyanobenzyl;

[0016] R 3 It represents hydrogen.

[0017] Preferably, the substituted C6-C 10 Arylsulfonyloxy groups are selected from:

[0018] .

[0019] Preferably, Selected from:

[0020] , .

[0021] More specifically, the above-mentioned benzodiazepine formamide compounds are selected from any of the following compounds:

[0022] code name Chemical name structural I-1 (1-Hydroxy-4-methyl-1,2-dihydrobenzo[d][1,2,3]diazaborane-2-formyl)glycine I-2 (1,6-Dihydroxy-1,2-dihydrobenzo[d][1,2,3]diazaborane-2-formyl)glycine I-3 (6-((4-chlorophenyl)sulfonyloxy)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaborane-2-formyl)glycine I-4 1,6-Dihydroxy-N-(pyridazin-4-yl)benzo[d][1,2,3]diazaboranebenzyl-2(1H)-formamide I-5 6-(4-trifluoromethoxybenzenesulfonyloxy)-1-hydroxy-2-(pyridazine-4-carbamoyl)-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-6 N-(4-cyanobenzyl)-1,6-dihydroxybenzo[d][1,2,3]diazaborane-2(1H)-formamide I-7 N-(4-cyanobenzyl)-1,7-dihydroxybenzo[d][1,2,3]diazaborane-2(1H)-formamide I-8 N-(4-cyanobenzyl)-1,5-dihydroxybenzo[d][1,2,3]diazaborane-2(1H)-formamide I-9 6-Benzenesulfonyloxy-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-10 6-(4-Methylbenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-11 7-(4-Methylbenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-12 5-(4-Methylbenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-13 6-(4-methoxybenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-14 6-(4-cyanobenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-15 6-(4-Chlorobenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-16 6-(3,4-Dichlorobenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-17 7-(2,4-Dichlorobenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene I-18 7-(2,3-dichlorobenzenesulfonyloxy)-2-((4-cyanobenzyl)carbamoyl)-1-hydroxy-1,2-dihydrobenzo[d][1,2,3]diazaboranebenzene

[0023] The pharmaceutically acceptable salts of the above-mentioned benzodiazepine formamides are salts formed by the compounds and bases, wherein the base is an inorganic base containing a basic metal cation, an alkaline earth metal cation, or an ammonium cation, or a pharmaceutically acceptable organic primary amine, secondary amine, or tertiary amine.

[0024] As a second aspect of the present invention, a method for preparing the above-mentioned benzodiazepine formamide compounds:

[0025]

[0026] Among them, R 1 R 2 R 3 The definitions of n are as described above.

[0027] The corresponding base is used to form a salt with the compound (I) prepared by the above method to obtain a pharmaceutically acceptable salt of the compound.

[0028] As a third aspect of the present invention, the pharmaceutical composition of the above-mentioned benzodiazepine formamide compounds includes the compound and a pharmaceutically acceptable carrier.

[0029] The aforementioned benzodiazepines can be combined with pharmaceutically acceptable carriers to form common pharmaceutical preparations, such as tablets, capsules, syrups, suspensions, or injections. These preparations can also contain commonly used pharmaceutical excipients such as flavorings, sweeteners, liquid / solid fillers, and diluents.

[0030] As a fourth aspect of the present invention, the above-mentioned benzodiazepine carboxamide compounds or pharmaceutical compositions thereof are used as PHD inhibitors for the treatment of ischemic diseases such as renal anemia.

[0031] The term "C1-C4 alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1-4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, etc.

[0032] The term "C1-C4 alkoxy" refers to O-C1-C4 alkyl, which is a straight-chain or branched alkoxy group having 1-4 carbon atoms, including but not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, etc.

[0033] The term "C1-C4 haloalkoxy" refers to a group formed by replacing a hydrogen atom in a C1-C4 alkoxy group with one or more halogen atoms, wherein the halogen includes fluorine, chlorine, bromine, iodine, and includes, but is not limited to, fluoromethoxy, chloromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, etc.

[0034] The term "C1-C2 carboxyalkyl" refers to a group formed by replacing an alkyl group with a carboxyl group, which has 1-2 carbon atoms, including but not limited to carboxymethyl, carboxyethyl, etc.

[0035] The term "5-6 member nitrogen-containing heteroaryl" refers to a 5-6 member aromatic ring group containing at least one nitrogen atom as a ring heteroatom, including but not limited to pyrrole, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, etc.

[0036] The term "C6-C" 10 "Aromatic sulfonyloxy" refers to C6-C 10 Aryl-S(O)2-O-, wherein C6-C 10 Aryl groups are aromatic hydrocarbon groups having 6-10 carbon atoms, including phenyl, naphthyl, etc., wherein the C6-C 10 Aryl sulfonyloxy groups include, but are not limited to, benzenesulfonyloxy and naphthalenesulfonyloxy groups.

[0037] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: The compounds of the present invention have significant inhibitory activity against PHD2, and the inhibitory activity can reach the nanomolar level, wherein the IC50 of compound I-5 is [missing information]. 50 The effective concentrations were 0.15 ± 0.02 μM for I-13, 0.24 ± 0.02 μM for I-14, 0.30 ± 0.06 μM for I-3, and 0.41 ± 0.06 μM for I-3. Some compounds showed better activity than the positive control roxadustat (IC50). 50The concentration was 0.23 ± 0.02 μM or equivalent, demonstrating excellent PHD2 inhibition ability. In the HRE dual-luciferase reporter gene assay of Hep3B cells, the representative compound can effectively regulate HRE-mediated luciferase activity, suggesting that it can inhibit PHD2, stabilize HIF and activate the transcription of downstream target genes of the HIF signaling pathway. Therefore, this type of compound can be used for the treatment of PHD2 / HIF pathway-related diseases, especially anemia and ischemia-related diseases such as renal anemia and chronic kidney disease anemia. This invention provides a new option for the treatment of related diseases. Attached Figure Description

[0038] Figure 1 The figure shows the test results of the regulatory effects of representative compounds on HIF transcriptional activity (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Detailed Implementation

[0039] Unified preparation method for Examples 1-18:

[0040]

[0041] Boronate (III) (0.2 mmol, 1.0 eq) was dissolved in 4 mL of acetonitrile, and 1 mL of the corresponding hydrazide (0.2 mmol, 1.0 eq) aqueous solution was added dropwise. The reaction was carried out at 37 °C for 1 h until complete. After the reaction was completed, acetonitrile and water were removed by vacuum distillation. 30 mL of water was added, and the mixture was extracted three times with ethyl acetate (50 mL). The organic layers were combined, washed once with saturated brine (30 mL), dried over anhydrous sodium sulfate, and the organic phase was concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to give compounds I-1 to I-18.

[0042] Example 1: The white solid was designated as compound I-1, with a yield of 92%. 1 H NMR (400 MHz, DMSO-d6) δ12.74 (s, br, 1H), 9.34 (s, 1H), 8.69 (t, J = 6.1 Hz, 1H), 8.11 (d, J = 7.4Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.85 (t, J = 7.6 Hz, 1H), 7.73 (t, J = 7.3Hz, 1H), 3.95 (d, J = 6.1 Hz, 2H), 2.60 (s, 3H). EI-MS m / z: 260.10 [MH] -

[0043] Example 2: The white solid was designated as compound I-2, with a yield of 91%. 1 H NMR (400 MHz, DMSO-d6) δ9.51 (s, 1H), 8.20 (t, J = 4.3 Hz, 1H), 8.09 (s, 1H), 7.89 (d, J = 8.0 Hz,1H), 7.17 – 7.10 (m, 2H), 3.51 (d, J = 4.0 Hz, 2H). EI-MS m / z: 261.94 [MH] - .

[0044] Example 3: The pale yellow solid was designated as compound I-3, with a yield of 86%. 1 H NMR (400 MHz, DMSO-d6) δ12.70 (s, br, 1H), 8.52 (t, J = 6.2 Hz, 1H), 7.91 – 7.86 (m, 3H), 7.76 (d, J= 8.7 Hz, 2H), 7.51 (d, J = 8.1 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 7.06 (dd,J = 8.0, 2.4 Hz, 1H), 3.63 (d, J = 5.7 Hz, 2H). EI-MS m / z: 435.78 [MH] -

[0045] Example 4: The yellow solid was designated as compound I-4, with a yield of 76%. 1 H NMR (400 MHz, DMSO-d6) δ10.88 (s, 1H), 10.46 (s, 1H), 9.63 (dd, J = 2.8, 1.1 Hz, 1H), 9.09 (dd, J =5.9, 1.0 Hz, 1H), 8.83 (s, 1H), 8.24 EI-MS m / z: 284.07 [M+H] +

[0046] Example 5: The white solid was designated as compound I-5, with a yield of 84%. 1H NMR (400 MHz, CDCl3) δ 10.77(s, 1H), 9.66 (d, J = 2.7 Hz, 1H), 9.06 (d, J = 5.9 Hz, 1H), 8.89 (s, 1H),8.22 – 8.13 (m, 3H), 8.02 – 7.96 EI-MS m / z: 506.07 [MH] -

[0047] Example 6: The white solid was designated as compound I-6, with a yield of 54%. 1 H NMR (400 MHz, CDCl3) δ 9.12(s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.98 (s, 1H), 7.85 (s, 1H), 7.66 (d, J =8.2 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 7.15 (dd, J = 8.2, 2.4 Hz, 1H), 7.04 (d, J = 2.4 Hz, 1H), 4.66 (d, J = 6.2 Hz, 2H). 13 C NMR (101 MHz, CDCl3) δ160.96, 160.72, 144.34, 140.96, 136.22, 133.20, 131.80, 127.74, 119.13,118.33, 112.41, 110.17, 42.67. EI-MS m / z: 319.10 [MH] -

[0048] Example 7: The white solid was designated as compound I-7, with a yield of 51%. 1 H NMR (400 MHz, CDCl3) δ 9.24(s, 1H), 8.04 (s, 1H), 7.86 (d, J = 0.6 Hz, 1H), 7.68 – 7.65 (m, 2H), 7.59 –7.55 (m, 2H), 7.50 – 7.47 (m, 2H), 7.24 – 7.20 (m, 1H), 4.66 (d, J = 6.3 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.85, 159.35, 144.35, 140.75, 131.77,129.57, 127.75, 126.82, 120.62, 118.29, 116.14, 110.15, 42.65. EI-MS m / z:310.10 [MH] -

[0049] Example 8: The white solid was designated as compound I-8, with a yield of 60%. 1 H NMR (400 MHz, CDCl3) δ 10.08(s, 1H), 9.34 (s, 1H), 8.75 (t, J = 6.3 Hz, 1H), 8.40 (s, 1H), 7.69 – 7.64(m, 2H), 7.57 – 7.51 (m, 3H), 7.44 (t, J = 7.7 Hz, 1H), 7.17 (dd, J = 8.0,1.2 Hz, 1H), 4.61 (d, J = 6.3 Hz, 2H). 13 C NMR (101 MHz, CDCl3) δ 160.84,154.94, 144.32, 136.44, 131.82, 131.32, 127.78, 122.28, 121.67, 118.33,117.76, 110.21, 42.70. EI-MS m / z: 319.10 [MH] -

[0050] Example 9: The white solid was designated as compound I-9, with a yield of 78%. 1 H NMR (400 MHz, CDCl3) δ 9.19(s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.96 (t, J = 5.8 Hz, 1H), 7.88 (s, 1H),7.87 – 7.83 (m, 2H), 7.70 (m, 1H), 7.68 – 7.64 (m, 2H), 7.58 – 7.53 (m, 2H), 7.50 – 7.45 (m, 2H), 7.42 (d, J = 2.1 Hz, 1H), 7.16 (dd, J = 8.2, 2.2 Hz,1H), 4.66 (d, J = 6.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.52, 152.44,143.46, 140.33, 135.96, 135.04, 134.63, 134.30, 132.56, 129.36, 128.44,128.03, 124.57, 120.81, 118.62, 111.52, 43.35. EI-MS m / z: 459.09 [MH] -

[0051] Example 10: The white solid was designated as compound I-10, with a yield of 62%. 1 H NMR (400 MHz, CDCl3) δ9.19 (s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.97 (t, J = 6.3 Hz, 1H), 7.88 (s,1H), 7.74 – 7.69 (m, 2H), 7.69 – 7.63 (m, 2H), 7.50 – 7.45 (m, 2H), 7.43 (d,J = 2.2 Hz, 1H), 7.36 – 7.30 (m, 2H), 7.14 (dd, J = 8.2, 2.2 Hz, 1H), 4.65(d, J = 6.3 Hz, 2H), 2.46 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 160.54, 152.53,145.92, 143.48, 140.40, 135.94, 134.24, 132.56, 131.99, 129.96, 128.46,128.03, 124.61, 120.85, 118.62, 111.49, 43.34, 21.74. EI-MS m / z: 473.11 [MH] -

[0052] Example 11: The white solid was designated as compound I-11, with a yield of 65%. 1H NMR (400 MHz, CDCl3) δ9.14 (s, 1H), 7.98 (t, J = 6.3 Hz, 1H), 7.92 (s, 1H), 7.76 – 7.72 (m, 2H), 7.71 (d, J = 2.5 Hz, 1H), 7.67 – 7.64 (m, 2H), 7.63 (d, J = 8.5 Hz, 1H), 7.50 (dd, J = 8.5, 2.5 Hz, 1H), 7.48 – 7.45 (m, 2H), 7.33 (d, J = 8.0 Hz, 2H), 4.65 (d, J = 6.3 Hz, 2H), 2.46 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 160.55,150.92, 145.83, 143.48, 140.35, 132.99, 132.58, 132.55, 132.17, 129.94,129.84, 129.63, 128.44, 128.33, 128.03, 127.06, 125.04, 118.61, 111.50,43.34, 21.73. EI-MS m / z: 473.11 [MH] -

[0053] Example 12: The white solid was designated as compound I-12, with a yield of 63%. 1 H NMR (400 MHz, CDCl3) δ9.20 (s, 1H), 8.15 – 8.10 (m, 2H), 7.98 (t, J = 6.3 Hz, 1H), 7.78 – 7.73 (m,2H), 7.70 – 7.63 (m, 2H), 7.57 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 1.1 Hz, 1H), 4.65 (d, J = 6.2 Hz, 2H), 2.46 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 160.49, 146.37, 146.18, 143.52,135.28, 132.55, 131.36, 130.81, 130.10, 128.49, 128.01, 127.82, 125.77,118.60, 111.36, 43.19, 21.68. EI-MS m / z: 473.11 [MH] -

[0054] Example 13: The white solid was designated as compound I-13, with a yield of 70%. 1 H NMR (400 MHz, CDCl3) δ9.19 (s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.97 (t, J = 6.3 Hz, 1H), 7.88 (s,1H), 7.77 – 7.74 (m, 2H), 7.68 – 7.64 (m, 2H), 7.49 – 7.45 (m, 2H), 7.42 (d,J = 2.1 Hz, 1H), 7.15 (dd, J = 8.2, 2.2 Hz, 1H), 6.99 – 6.95 (m, 2H), 4.65(d, J = 6.3 Hz, 2H), 3.89 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 164.40, 160.54,152.60, 143.44, 140.45, 135.94, 134.23, 132.57, 130.74, 128.02, 126.21,124.72, 120.93, 118.61, 114.51, 111.54, 55.78, 43.35. EI-MS m / z: 489.11 [MH] -

[0055] Example 14: The white solid was designated as compound I-14, with a yield of 70%. 1H NMR (400 MHz, CDCl3) δ9.20 (s, 1H), 8.20 (d, J = 8.3 Hz, 1H), 8.02 – 7.94 (m, 3H), 7.89 (s, 1H),7.86 (d, J = 8.4 Hz, 2H), 7.68 – 7.63 (m, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 2.2 Hz, 1H), 7.20 (dd, J = 8.3, 2.2 Hz, 1H), 4.66 (d, J = 6.2 Hz, 2H). 13 C NMR (101 MHz, CDCl3) δ 160.43, 151.97, 143.38, 140.05, 139.18,136.11, 134.67, 133.12, 132.58, 129.06, 128.04, 124.17, 120.52, 118.60,118.41, 116.71, 111.55, 77.26, 43.37. EI-MS m / z: 484.09 [MH] -

[0056] Example 15: The white solid was designated as compound I-15, yield 66%. 1 H NMR (400 MHz, CDCl3) δ9.20 (s, 1H), 8.18 (d, J = 8.2 Hz, 1H), 7.96 (t, J = 6.1 Hz, 1H), 7.89 (d, J= 0.6 Hz, 1H), 7.80 – 7.76 (m, 2H), 7.68 – 7.65 (m, 2H), 7.55 – 7.51 (m, 2H), 7.50 – 7.46 (m, 2H), 7.42 (d, J = 2.2 Hz, 1H), 7.19 (dd, J = 8.2, 2.2 Hz,1H), 4.66 (d, J = 6.3 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 160.48, 152.28,143.47, 141.53, 140.30, 140.28, 136.03, 134.45, 133.44, 132.57, 129.81,129.75, 128.02, 124.43, 120.68, 118.58, 111.42, 43.23. EI-MS m / z: 493.05 [MH] -

[0057] Example 16: The white solid was designated as compound I-16, yield 59%. 1 H NMR (400 MHz, CDCl3) δ9.21 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.00 – 7.94 (m, 2H), 7.91 (s, 1H),7.69 – 7.63 (m, 4H), 7.48 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 2.2 Hz, 1H), 7.23 (dd, J = 8.3, 2.2 Hz, 1H), 4.66 (d, J = 6.2 Hz, 2H). 13 C NMR (151 MHz, CDCl3)δ 160.46, 152.09, 143.45, 140.22, 140.20, 136.10, 134.60, 132.57, 131.44,130.17, 128.03, 127.30, 124.29, 120.57, 118.58, 111.43, 43.23. EI-MS m / z:527.02 [MH] -

[0058] Example 17: The white solid was designated as compound I-17, with a yield of 58%. 1 H NMR (400 MHz, CDCl3) δ9.18 (s, 1H), 7.99 – 7.88 (m, 4H), 7.65 (dd, J = 8.3, 2.0 Hz, 4H), 7.58 (dd,J = 8.5, 2.5 Hz, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.36 (dd, J = 8.6, 2.1 Hz,1H), 4.65 (d, J = 6.2 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 160.47, 150.45,143.50, 141.68, 140.24, 134.39, 133.27, 133.13, 132.55, 132.19, 131.89,129.86, 128.02, 127.57, 126.56, 124.58, 118.58, 111.36, 43.21. EI-MS m / z:527.02 [MH] -

[0059] Example 18: The white solid was designated as compound I-18, with a yield of 62%. 1 H NMR (400 MHz, CDCl3) δ9.17 (s, 1H), 7.98 – 7.91 (m, 4H), 7.78 (dd, J = 8.1, 1.5 Hz, 1H), 7.67 –7.64 (m, 3H), 7.57 (dd, J = 8.5, 2.5 Hz, 1H), 7.48 – 7.45 (m, 2H), 7.34 (t, J= 8.1 Hz, 1H), 4.65 (d, J = 6.2 Hz, 2H). 13 C NMR (101 MHz, CDCl3) δ 160.46,150.50, 143.42, 140.19, 136.40, 136.14, 135.58, 133.24, 132.57, 131.86,130.54, 129.84, 128.04, 127.42, 126.51, 124.65, 118.59, 111.56, 43.36. EI-MSm / z: 527.02 [MH] -

[0060] Test Implementation Example:

[0061] 1. Inhibitory activity of the compound against PHD2 – measured using fluorescence polarization (FP) method.

[0062] The pET28a vector encoding PHD2 (181-426) with an N-terminal His6 tag was purchased from Nanjing Zhongding Biotechnology Co., Ltd. The PHD2 (181-426) protein was obtained by inducing expression of the recombinant plasmid in *E. coli* BL21 at 20 °C for 16 h. After cell lysis, the clear lysate was collected by centrifugation and purified using a HisTrap affinity chromatography column (GE Healthcare) via imidazole gradient elution. The purified protein was then stored in PBS buffer. The ability of the compound to competitively bind to the PHD2 protein with a fluorescently labeled small molecule probe was tested using a 384-well plate (Corning #3575). The final test volume was 60 μL. The tested compound and fluorescent probe were dissolved in DMSO and pure water, respectively, for later use. The compounds were serially diluted to different concentration gradients using assay buffer (containing 10 mM Hepes, 150 mM NaCl, and 0.05% (v / v) Tween-20, pH 7.4). Each well was then filled with the diluted compound, 5 nM fluorescent probe, and 25 nM PHD2 (181-426) protein. Assay buffer was added to a final volume of 60 μL, ensuring the DMSO content was less than 1%. Two replicates were set for each compound concentration. A blank control (fluorescent probe + assay buffer, no protein or inhibitor) and a negative control (fluorescent probe + PHD2 protein + assay buffer, no inhibitor) were included in each experiment. The plates were incubated at room temperature for 60 min. The plates were then scanned using a Spark multi-mode microplate reader (Tecan) with excitation wavelength set to 485 ± 25 nm and emission wavelength set to 535 ± 25 nm. The calculation formula is: % Inhibition rate = 100 × [1 - (Measured value - Blank) / (Negative value - Blank)], which gives the inhibition rate corresponding to a specific concentration. The obtained data is imported into GraphPad Prism 10.6.1, and the IC50 is obtained through nonlinear least squares analysis. 50 Values. The test results for compound FP are shown in Table 1.

[0063] Table 1. PHD2 inhibitory activity of the compounds in this invention

[0064] Compound numbering <![CDATA[PHD2 IC 50 (μM)]]> Compound numbering <![CDATA[PHD2 IC 50 (μM)]]> Ⅰ-1 15.24 ± 2.32 Ⅰ-11 1.69 ± 0.09 Ⅰ-2 16.70 ± 2.40 Ⅰ-12 0.83 ± 0.08 Ⅰ-3 0.41 ± 0.06 Ⅰ-13 0.24 ± 0.02 Ⅰ-4 2.05 ± 0.04 Ⅰ-14 0.30 ± 0.06 Ⅰ-5 0.15 ± 0.02 Ⅰ-15 1.07 ± 0.14 Ⅰ-6 3.42 ± 0.08 Ⅰ-16 1.51 ± 1.33 Ⅰ-7 1.63 ± 0.23 Ⅰ-17 1.09 ± 0.20 Ⅰ-8 0.79 ± 0.03 Ⅰ-18 1.22 ± 0.18 Ⅰ-9 0.83 ± 0.08 Roxadustat 0.23 ± 0.02 Ⅰ-10 0.62 ± 0.02

[0065] 2. Regulatory effects of compounds on HIF transcriptional activity – HRE dual-luciferase reporter gene assay

[0066] The effects of compounds on the regulation of HRE-mediated gene transcription activity in cells were tested using 48-well cell culture plates with Hep3B cells as the experimental model. The HRE-driven firefly luciferase reporter plasmid and the SV40 promoter-regulated Renilla luciferase internal control plasmid were both purified using a plasmid extraction kit (Tiangen Biotech). The compounds were serially diluted to a series of concentrations in complete culture medium. Logarithmically growing Hep3B cells were seeded into 48-well plates and cultured for 24 h before transfection. 0.4 μg of mixed plasmid DNA was added to each well, and co-transfection was performed using 1 μL of Lipofectamine 2000 transfection reagent (Invitrogen) for 6 h. Three replicates were set for each compound concentration. A blank control (plasmid transfection only, no compound treatment) and a solvent control (plasmid transfection with an equal volume of solvent) were included in each experiment. After transfection, fresh culture medium was added, and the corresponding concentration of the test compound was added for another 24 h. After cell lysis, reaction substrates corresponding to firefly luciferase and Renilla luciferase were added, respectively. The activity signals of the two luciferases were detected using a Spark Tecan multi-mode plate reader. The calculation formula was: Relative HRE reporter activity = Firefly luciferase signal value / Renilla luciferase signal value. The obtained data were imported into GraphPad Prism 10.6.1 for analysis. Results for representative compounds are shown below. Figure 1 .

Claims

1. A benzodiazepine formamide compound or a pharmaceutically acceptable salt thereof, characterized in that, It has the structure of formula (Ⅰ): in: R 1 It is hydrogen, hydroxyl, substituted or unsubstituted C6-C 10 Arylsulfonyloxy, substituted C6-C 10 The number of substituents in the arylsulfonyloxy group is one or two, and the substituents are C1-C4 alkyl, C1-C4 alkoxy, cyano, halogen or C1-C4 haloalkoxy; n is 0 or 1; R 2 It can be C1-C2 carboxylalkyl, carboxyl, 5-6 nitrogen-containing heteroaryl, or p-cyanophenyl; R 3 It is hydrogen or C1-C4 alkyl.

2. The benzodiazepine formamide compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 1 It is a benzenesulfonyloxy group that is hydrogen, hydroxyl, substituted or unsubstituted, wherein the number of substituents in the substituted benzenesulfonyloxy group is 1 or 2, and the substituents are methyl, methoxy, cyano, chlorine or trifluoromethoxy; n is 0; R 2 It is carboxymethyl, pyridazinyl, or p-cyanobenzyl; R 3 It is hydrogen.

3. The benzodiazepine formamide compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: Replacement C6-C 10 Arylsulfonyloxy groups are selected from: 。 4. The benzodiazepine formamide compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: Selected from: , .

5. The benzodiazepine formamide compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that, The compound is selected from any one of the following compounds:

6. The benzodiazepine carboxamide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that, The pharmaceutically acceptable salt is the salt formed by the compound and a base, wherein the base is an inorganic base containing a basic metal cation, an alkaline earth metal cation, or an ammonium cation salt, or a pharmaceutically acceptable organic primary amine, secondary amine, or tertiary amine.

7. A method for preparing a benzodiazepine formamide compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 5, characterized in that, The preparation method is as follows: Compound (Ⅲ) was condensed and then subjected to an intramolecular cyclization reaction to yield the target compound; Among them, R 1 R 2 R 3 The definitions of n are as described in any one of claims 1 to 3; Or, the corresponding base can be reacted with the compound prepared by the above method ( ( ) to form a salt, that is, to obtain a pharmaceutically acceptable salt of the compound.

8. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises any one of the benzodiazepine carboxamide compounds of claims 1 to 5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. The use of any benzodiazepine carboxamide compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 5 in the preparation of a prolyl hydroxylase inhibitor drug.

10. The application according to claim 9, characterized in that, The drug is used to treat ischemic diseases.